Skip to main content

Remote Job Finders (RJF)

A new survey from CRB showed that most manufacturing initiatives in the U.S. made in response to tariffs are coming from Big Pharma companies, while smaller biotechs are left to hope “the situation doesn’t get worse.”
Most Life Sciences Companies Not Planning New Investments After Tariffs: Report
Scroll to top